



## CR Ventures Ends First Year with Two High-Profile Investments

*BOSTON, December 22, 2020.* **Clinical Research Ventures** (CR Ventures), the global clinical trial-focused investment fund, is celebrating the completion of its first full year of activity after closing investments in Boston-based startup **Astrocyte Pharmaceuticals, Inc.** and Swiss anti-infectives company **BioVersys AG**. Both companies are entering clinical trials with drugs for some of the most difficult and important unmet medical needs.

Astrocyte is developing innovative neuroprotective therapies for **traumatic brain injuries, stroke, and concussions**. The Company's approach enhances the mitochondrial energy production of astrocytes, enhancing multiple healing mechanisms, including protection against edema, glutamate excitotoxicity, and oxidative stress. CR Ventures is the largest investor in Astrocyte's USD 5 million series A round, which will enable the Company to carry out Phase I trials for its neuroprotective agent AST-004. See [www.astrocytapharma.com](http://www.astrocytapharma.com).

BioVersys focuses on the combat against antimicrobial drug resistance using Transcriptional Regulator Inhibitory Compounds (TRIC) and direct acting molecules. The Company's USD 20 million series B round will allow advancing its two lead assets for **multi-drug resistant bacterial infections** through initial clinical trials. In November BioVersys announced it had successfully dosed the first patients in its phase I trial with BV100. See press release [here](#).

Peter Kovacs, one of CR Ventures' four founding partners, remarked, "Our investments in Astrocyte and BioVersys advance our mission of supporting exceptional companies at a point when it's typically difficult to secure investment, namely the start of clinical trials."

CR Ventures is now actively looking at possible investments in a wide range of European and North American clinical-stage biotech and medtech companies, including several with names starting with the letter C.

### About Clinical Research Ventures

Clinical Research Ventures supports the work of early-stage biotech companies taking on some of today's most challenging unmet medical needs. CR Ventures' focus is investing in innovative companies as they enter Phase I and Phase II clinical trials.

Investors and companies with relevant investment opportunities are invited to contact CR Ventures through <https://cr-ventures.com/start-here/> or [ContactUs@cr-ventures.com](mailto:ContactUs@cr-ventures.com).